ARTICLE | Clinical News
Stelara ustekinumab regulatory update
December 7, 2015 8:00 AM UTC
Johnson & Johnson submitted regulatory applications to FDA and EMA for Stelara ustekinumab to treat moderately to severely active Crohn’s disease (CD). The human mAb inhibiting IL-12 and IL-23 is appr...